{
  "abstract": "Iron overload after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is associated with oxidative stress and adverse outcomes. Although deferasirox reduces ferritin, its effect on survival remains incompletely characterized. We conducted a prospective observational study across 7 French centers, enrolling 41 patients with acute myeloid leukemia or myelodysplastic syndromes who initiated deferasirox 6 months after allo-HSCT. Eligibility required complete remission, iron overload (ferritin level >1000 μg/L), and preserved organ function. Outcomes were compared with propensity score-matched controls (1:2) from the SFGM-TC registry. End points were overall survival (OS), progression-free survival (PFS), transplant-related mortality (TRM), relapse, and safety. Analyses employed exact matching, inverse probability of treatment weighting (IPTW), and multivariable Cox models. Ferritin level decreased from 1700 μg/L to <1000 μg/L by 18 months. Across analytic methods, deferasirox was associated with a reduced hazard of progression or death (PFS: hazard ratio [HR], 0.41-0.44) and a reduced hazard of mortality (OS: HR, 0.28-0.43). TRM was significantly reduced in propensity score matching and Cox models (HR, 0.21), whereas the IPTW analysis yielded a comparable point estimate (HR, 0.24) that did not reach the significance threshold (P = .063). The probability of relapse (estimated via cumulative incidence of relapse) did not differ significantly. Adverse events were predominantly renal and manageable. Initiating deferasirox 6 months after allo-HSCT was associated with sustained ferritin reduction, a reduced hazard of progression or death (PFS), lower TRM, and a favorable although nonsignificant hazard of mortality (OS), with acceptable safety. These findings support deferasirox as a feasible posttransplant intervention, warranting confirmation in randomized trials.",
  "abstract_shown": true,
  "affiliations": [],
  "article_type": null,
  "arxiv": null,
  "author_total": 12,
  "authors": [
    {
      "name": "Romain Buono"
    },
    {
      "name": "Anne Huynh"
    },
    {
      "name": "Edouard Forcade"
    },
    {
      "name": "Hélène Labussière"
    },
    {
      "name": "Patrice Ceballos"
    },
    {
      "name": "Jérôme Cornillon"
    },
    {
      "name": "Quentin Cabrera"
    },
    {
      "name": "Maud D’aveni"
    },
    {
      "name": "Marie Robin"
    },
    {
      "name": "Raynier Devillier"
    },
    {
      "name": "Nicole Raus"
    },
    {
      "name": "Mauricette Michallet"
    }
  ],
  "bibtex": "https://research.draconitic.com/paper/456nce0x411s1.bib",
  "cited_by": 0,
  "doi": "10.1182/bloodadvances.2025018894",
  "fulltext_url": null,
  "id": "456nce0x411s1",
  "issns": [
    "2473-9529",
    "2473-9537"
  ],
  "landing_url": "https://hal.univ-lorraine.fr/hal-05787682v1",
  "language": "en",
  "licence": "CC-BY-NC-ND",
  "licence_label": "CC BY-NC-ND",
  "licence_source": "journal",
  "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/",
  "metadata_licence": null,
  "native_subjects": [
    [
      "hal",
      "0.sdv"
    ],
    [
      "openalex",
      "2720|Hematopoietic Stem Cell Transplantation"
    ]
  ],
  "openalex": "W7135030150",
  "pdf_url": "https://ashpublications.org/bloodadvances/article-pdf/doi/10.1182/bloodadvances.2025018894/2508724/bloodadvances.2025018894.pdf",
  "pmcid": null,
  "pmid": null,
  "published": "2026-05-26",
  "publisher": "The American Society of Hematology",
  "ris": "https://research.draconitic.com/paper/456nce0x411s1.ris",
  "sources": [
    {
      "first_seen": "2026-10-30T12:17:51Z",
      "native_id": "hal-05787682",
      "source": "hal",
      "url": "https://hal.univ-lorraine.fr/hal-05787682v1"
    }
  ],
  "subjects": [
    {
      "field": "biology",
      "origin": "hal:0.sdv",
      "subfield": "general"
    }
  ],
  "title": "Deferasirox 6 months after allo-HSCT in AML/MDS: a prospective propensity-matched study",
  "title_text": "Deferasirox 6 months after allo-HSCT in AML/MDS: a prospective propensity-matched study",
  "type": "peer-reviewed",
  "updated_at": "2026-10-30T12:17:51Z",
  "url": "https://research.draconitic.com/paper/456nce0x411s1",
  "venue": "Blood Advances",
  "versions": []
}